Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

Júlia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Cañete, Antonio Barreiro, Luis González-González, Laia Madrenas, Irina Güell, Bonaventura Clotet, View ORCID ProfileNuria Izquierdo-Useros, Dàlia Raïch-Regué, Marçal Gallemí, Julià Blanco, View ORCID ProfileEdwards Pradenas, Benjamin Trinité, Julia G Prado, Oscar Blanch-Lombarte, Raúl Pérez-Caballero, Montserrat Plana, Ignasi Esteban, Carmen Pastor-Quiñones, Xavier Núñez-Costa, Rachel Abu Taleb, Paula McSkimming, Alex Soriano, Jocelyn Nava, Jesse Omar Anagua, Rafel Ramos, Ruth Martí Lluch, Aida Corpes Comes, Susana Otero Romero, Xavier Martinez Gomez, Carla Sans-Pola, José Moltó, Susana Benet, Lucía Bailón, Jose R Arribas, Alberto M Borobia, Javier Queiruga Parada, Jorge Navarro-Pérez, Maria José Forner Giner, Rafael Ortí Lucas, María del Mar Vázquez Jiménez, Salvador Oña Compán, Melchor Alvarez-Mon, Daniel Troncoso, Eunate Arana-Arri, Susana Meijide, Natale Imaz-Ayo, Patricia Muñoz García, Sofía de la Villa Martínez, Sara Rodríguez Fernández, Teresa Prat, Èlia Torroella, Laura Ferrer
doi: https://doi.org/10.1101/2022.07.05.22277210
Júlia Corominas
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carme Garriga
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoni Prenafeta
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Moros
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Cañete
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Barreiro
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis González-González
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laia Madrenas
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irina Güell
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bonaventura Clotet
bIrsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, Can Ruti Campus, 08916, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nuria Izquierdo-Useros
bIrsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, Can Ruti Campus, 08916, Badalona, Spain
oCIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nuria Izquierdo-Useros
Dàlia Raïch-Regué
bIrsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, Can Ruti Campus, 08916, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marçal Gallemí
bIrsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, Can Ruti Campus, 08916, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julià Blanco
bIrsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, Can Ruti Campus, 08916, Badalona, Spain
oCIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain
rInfectious Diseases and Immunity, Faculty of Medicine, Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Carrer de la Sagrada Família, 7, 08500 Vic, Spain
sGermans Trias i Pujol Research Institute (IGTP), Carretera de Canyet, s/n, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edwards Pradenas
bIrsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, Can Ruti Campus, 08916, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edwards Pradenas
Benjamin Trinité
bIrsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, Can Ruti Campus, 08916, Badalona, Spain
oCIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia G Prado
bIrsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, Can Ruti Campus, 08916, Badalona, Spain
oCIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain
sGermans Trias i Pujol Research Institute (IGTP), Carretera de Canyet, s/n, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oscar Blanch-Lombarte
bIrsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, Can Ruti Campus, 08916, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raúl Pérez-Caballero
bIrsiCaixa AIDS Research Institute, Carretera de Canyet, s/n, Can Ruti Campus, 08916, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Montserrat Plana
cAIDS Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/ del Rosselló, 149, 08036 Barcelona, Spain
oCIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ignasi Esteban
cAIDS Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/ del Rosselló, 149, 08036 Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen Pastor-Quiñones
cAIDS Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/ del Rosselló, 149, 08036 Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Núñez-Costa
dVeristat, LLC, Barcelona, Spain, Toronto, Canada, Pickmere, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Abu Taleb
dVeristat, LLC, Barcelona, Spain, Toronto, Canada, Pickmere, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula McSkimming
dVeristat, LLC, Barcelona, Spain, Toronto, Canada, Pickmere, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Soriano
eHospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C. de Villarroel, 170, 08036 Barcelona, Spain
oCIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jocelyn Nava
eHospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C. de Villarroel, 170, 08036 Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesse Omar Anagua
eHospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C. de Villarroel, 170, 08036 Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafel Ramos
fInstitut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Biomedical Research Institute, Girona (IdIBGi), Catalan Institute of Health, Carrer del Dr. Castany, s/n, 17190 Salt, Girona, Spain
pDepartment of Medical Sciences, School of Medicine, University of Girona, Plaça de Sant Domènec, 3, 17004 Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Martí Lluch
fInstitut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Biomedical Research Institute, Girona (IdIBGi), Catalan Institute of Health, Carrer del Dr. Castany, s/n, 17190 Salt, Girona, Spain
pDepartment of Medical Sciences, School of Medicine, University of Girona, Plaça de Sant Domènec, 3, 17004 Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aida Corpes Comes
fInstitut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Biomedical Research Institute, Girona (IdIBGi), Catalan Institute of Health, Carrer del Dr. Castany, s/n, 17190 Salt, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susana Otero Romero
gHospital Universitari Vall d’Hebron, Pg. de la Vall d’Hebron, 119, 08035, Barcelona, Spain
qUnitat Docent Vall d’Hebron, Universitat Autònoma de Barcelona, Plaça Cívica, 08193 Bellaterra, Barcelona, Spain
vCentro de Esclerosis Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Pg. de la Vall d’Hebron, 119, 08035, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Martinez Gomez
gHospital Universitari Vall d’Hebron, Pg. de la Vall d’Hebron, 119, 08035, Barcelona, Spain
qUnitat Docent Vall d’Hebron, Universitat Autònoma de Barcelona, Plaça Cívica, 08193 Bellaterra, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla Sans-Pola
gHospital Universitari Vall d’Hebron, Pg. de la Vall d’Hebron, 119, 08035, Barcelona, Spain
wDepartment of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Plaça Cívica, 08193, Bellaterra, Barcelona, Spain
xClinical Pharmacology Research Group, Vall d’Hebron Institut de Recerca, Pg. de la Vall d’Hebron, 119, 08035, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Moltó
hInfectious Diseases Department. Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, Spain
oCIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susana Benet
hInfectious Diseases Department. Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucía Bailón
hInfectious Diseases Department. Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose R Arribas
iInfectious Diseases Unit. Internal Medicine Department. La Paz University Hospital, IdiPAZ, C. de Pedro Rico, 6, 28029 Madrid, Spain
oCIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto M Borobia
iInfectious Diseases Unit. Internal Medicine Department. La Paz University Hospital, IdiPAZ, C. de Pedro Rico, 6, 28029 Madrid, Spain
oCIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain
tSpanish Clinical Research Network – SCReN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Queiruga Parada
iInfectious Diseases Unit. Internal Medicine Department. La Paz University Hospital, IdiPAZ, C. de Pedro Rico, 6, 28029 Madrid, Spain
tSpanish Clinical Research Network – SCReN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Navarro-Pérez
jHospital Clínico Universitario Valencia, Av. de Blasco Ibáñez, 17, 46010 València, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria José Forner Giner
jHospital Clínico Universitario Valencia, Av. de Blasco Ibáñez, 17, 46010 València, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael Ortí Lucas
jHospital Clínico Universitario Valencia, Av. de Blasco Ibáñez, 17, 46010 València, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María del Mar Vázquez Jiménez
kHospital Regional Universitario de Málaga, Av. de Carlos Haya, 84, 29010, Málaga, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salvador Oña Compán
kHospital Regional Universitario de Málaga, Av. de Carlos Haya, 84, 29010, Málaga, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melchor Alvarez-Mon
lHospital Universitario Príncipe de Asturias, Av. Principal de la Universidad, s/n, 28805 Alcalá de Henares, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Troncoso
lHospital Universitario Príncipe de Asturias, Av. Principal de la Universidad, s/n, 28805 Alcalá de Henares, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eunate Arana-Arri
mScientific Coordination, Biocruces Bizkaia HRI, Osakidetza, Cruces Plaza, 48903 Barakaldo, Bizkaia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susana Meijide
mScientific Coordination, Biocruces Bizkaia HRI, Osakidetza, Cruces Plaza, 48903 Barakaldo, Bizkaia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natale Imaz-Ayo
mScientific Coordination, Biocruces Bizkaia HRI, Osakidetza, Cruces Plaza, 48903 Barakaldo, Bizkaia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Muñoz García
nInstituto de Investigación Sanitaria Hospital Gregorio Marañón, C. del Dr. Esquerdo, 46, 28007 Madrid, Spain
uCIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofía de la Villa Martínez
nInstituto de Investigación Sanitaria Hospital Gregorio Marañón, C. del Dr. Esquerdo, 46, 28007 Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Rodríguez Fernández
nInstituto de Investigación Sanitaria Hospital Gregorio Marañón, C. del Dr. Esquerdo, 46, 28007 Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Prat
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: teresa.prat{at}hipra.com
Èlia Torroella
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Ferrer
aHIPRA, Avinguda de la Selva, 135, 17170 Amer, Girona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown to be safe and welltolerated in healthy young adults in a first-in-human, Phase I/IIa study dose-escalation trial. Here, we report the interim results of the Phase IIb HH-2, where the immunogenicity and safety of a heterologous booster with PHH-1V is assessed versus a homologous booster with BNT162b2 at 14, 28 and 98 days after vaccine administration.

Methods The HH-2 study is an ongoing multicentre, randomised, active-controlled, double-blind, non-inferiority Phase IIb trial, where participants 18 years or older who had received two doses of BNT162b2 were randomly assigned in a 2:1 ratio to receive a booster dose of vaccine —either heterologous (PHH-1V group) or homologous (BNT162b2 group)— in 10 centres in Spain. Eligible subjects were allocated to treatment stratified by age group (18-64 versus ≥65 years) with approximately 10% of the sample enrolled in the older age group. The primary endpoints were humoral immunogenicity measured by changes in levels of neutralizing antibodies (PBNA) against the ancestral Wuhan-Hu-1 strain after the PHH-1V or the BNT162b2 boost, and the safety and tolerability of PHH-1V as a boost. The secondary endpoints were to compare changes in levels of neutralizing antibodies against different variants of SARS-CoV-2 and the T-cell responses towards the SARS-CoV-2 spike glycoprotein peptides. The exploratory endpoint was to assess the number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster. This study is ongoing and is registered with ClinicalTrials.gov, NCT05142553.

Findings From 15 November 2021, 782 adults were randomly assigned to PHH-1V (n=522) or BNT162b2 (n=260) boost vaccine groups. The geometric mean titre (GMT) ratio of neutralizing antibodies on days 14, 28 and 98, shown as BNT162b2 active control versus PHH-1V, was, respectively, 1·68 (p<0·0001), 1·31 (p=0·0007) and 0·86 (p=0·40) for the ancestral Wuhan-Hu-1 strain; 0·62 (p<0·0001), 0·65 (p<0·0001) and 0·56 (p=0·003) for the Beta variant; 1·01 (p=0·92), 0·88 (p=0·11) and 0·52 (p=0·0003) for the Delta variant; and 0·59 (p=<0·0001), 0·66 (p<0·0001) and 0·57 (p=0·0028) for the Omicron BA.1 variant. Additionally, PHH-1V as a booster dose induced a significant increase of CD4+ and CD8+ T-cells expressing IFN-γ on day 14. There were 458 participants who experienced at least one adverse event (89·3%) in the PHH-1V and 238 (94·4%) in the BNT162b2 group. The most frequent adverse events were injection site pain (79·7% and 89·3%), fatigue (27·5% and 42·1%) and headache (31·2 and 40·1%) for the PHH-1V and the BNT162b2 groups, respectively. A total of 52 COVID-19 cases occurred from day 14 post-vaccination (10·14%) for the PHH-1V group and 30 (11·90%) for the BNT162b2 group (p=0·45), and none of the subjects developed severe COVID-19.

Interpretation Our interim results from the Phase IIb HH-2 trial show that PHH-1V as a heterologous booster vaccine, when compared to BNT162b2, although it does not reach a non-inferior neutralizing antibody response against the Wuhan-Hu-1 strain at days 14 and 28 after vaccination, it does so at day 98. PHH-1V as a heterologous booster elicits a superior neutralizing antibody response against the previous circulating Beta and the currently circulating Omicron BA.1 SARS-CoV-2 variants in all time points assessed, and for the Delta variant on day 98 as well. Moreover, the PHH-1V boost also induces a strong and balanced T-cell response. Concerning the safety profile, subjects in the PHH-1V group report significantly fewer adverse events than those in the BNT162b2 group, most of mild intensity, and both vaccine groups present comparable COVID-19 breakthrough cases, none of them severe.

Funding HIPRA SCIENTIFIC, S.L.U.

Competing Interest Statement

The authors of this manuscript declare: J Blanco has received institutional grants from HIPRA, Grifols, and MSD, royalties for licensed patent from AlbaJuna, honoraria for lectures from FLS Science and CIBER, supporting for meeting and/or travel from Gilead, and unpaid independent COVID-19 monitoring from GMCSC (Multidisciplinary Collaborative Group for the Scientific Monitoring of COVID-19) and unpaid participation in COVID-19 advisory group for CCAC (Comite Cientific Assessor de la COVID-19). Outside of this work, J Blanco is the CEO, founder and shareholder of AlbaJuna Therapeutics, S.L. J Corominas, C Garriga, A Barreiro, L Gonzalez-Gonzalez, L Madrenas, I Guell, D Raich-Regue, J G Prado, T Prat, E Torroella, B Trinite, L Ferrer, M Canete and A Prenafeta have received funding from HIPRA. The funding from HIPRA to R Ramos was paid to his institution. A Soriano has received grants from Pfizer and Gilead Sciences, consulting fees from Pfizer, MSD and Shionogi, and honoraria for lectures for Pfizer, MSD, Gilead Sciences, Shionogi, Angelini, and Menarini. B Trinite declares royalties by an institutional agreement and consulting fees for HIPRA, and is an unpaid member in advisory board for the Health Department of the Generalitat de Catalunya. N Izquierdo-Useros, D Raich-Regue and M Gallemi declare institutional grants from HIPRA, Pharma Mar, Grifols, Dentaid, Palobiofarma, Mynorix and Amassence. N Izquierdo-Useros and M Gallemi have received speaking honoraria from FLS Science. JR Arribas has received consulting fees and payment for participating in advisory board from Gilead Sciences, MSD, GSK, Eli Lilly, Roche, Pfizer and Sobi, honoraria for lectures and support for meetings and/or travel from MSD. A Borobia has received grants from GSK, Moderna and Janssen, speaking honoraria for Janssen, Gilead Sciences and Pfizer, and payment for participating in advisory board for Pfizer, Janssen and MDI. PM Garcia has received consulting fees and speaking honoraria from Gilead Sciences, Mundipharma and Pfizer, payment for expert testimony and participated in advisory board for Gilead Sciences and received support for meeting and/or travel from Pfizer. S Otero-Romero has received speaking honoraria from Genzyme, Biogen-Idec, Novartis, Roche, and MSD. Julia G Prado declares institutional grants from Grifols.

J Corominas, C Garriga, A Prenafeta, A Moros, M Canete, A Barreiro, L Gonzalez-Gonzalez, L Madrenas, I Guell, T Prat, E Torroella and L Ferrer are employees of HIPRA. Some of these authors may have stocks of HIPRA.

Several patent applications have been filed by HIPRA SCIENTIFIC S.L.U. and Laboratorios HIPRA, S.A. on different SARS-CoV-2 vaccine candidates and SARS-CoV-2 subunit vaccines, including the novel recombinant RBD fusion heterodimer PHH-1V. A Barreiro, J Corominas, A Prenafeta, L Gonzalez-Gonzalez, L Madrenas, L Ferrer, E Torroella, T Prat and C Garriga are the inventors of these patent applications. N Izquierdo-Useros is a patent inventor with no economical compensation for Pharma Mar and Mynorix.

The other authors have no relevant conflicts of interest to declare.

Clinical Trial

NCT05142553

Funding Statement

This work was supported by HIPRA SCIENTIFIC, S.L.U (HIPRA) and partially funded by the Centre for the Development of Industrial Technology (CDTI, IDI-20211192), a public organisation answering to the Spanish Ministry of Science and Innovation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was conducted in accordance with the Declaration of Helsinki, the Good Clinical Practice guidelines, and national regulations. The study protocol was reviewed and approved by the Spanish Agency of Medicines and Medical Devices (AEMPS) as well as Independent Ethics Committee from the Hospital Clinic de Barcelona. Written informed consent was obtained from all participants before enrolment. The biologic biosafety committee of the Research Institute Germans Trias and Pujol approved the execution of SARS-CoV-2 experiments at the BSL3 laboratory of the Centre for Bioimaging and Comparative Medicine (CSB-20-015-M8).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • We have: i) revised the conflicts of interest statements, ii) modified the adverse events data to a graphic presentation instead of Table, iii) we've added an analysis in a sub-population excluding those participants who informed COVID-19 infection.

Data Availability

All data relevant to the study are included in the article or uploaded as supplementary information. Further data are available from the authors upon reasonable request and with permission of HIPRA S.A.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 02, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
Júlia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Cañete, Antonio Barreiro, Luis González-González, Laia Madrenas, Irina Güell, Bonaventura Clotet, Nuria Izquierdo-Useros, Dàlia Raïch-Regué, Marçal Gallemí, Julià Blanco, Edwards Pradenas, Benjamin Trinité, Julia G Prado, Oscar Blanch-Lombarte, Raúl Pérez-Caballero, Montserrat Plana, Ignasi Esteban, Carmen Pastor-Quiñones, Xavier Núñez-Costa, Rachel Abu Taleb, Paula McSkimming, Alex Soriano, Jocelyn Nava, Jesse Omar Anagua, Rafel Ramos, Ruth Martí Lluch, Aida Corpes Comes, Susana Otero Romero, Xavier Martinez Gomez, Carla Sans-Pola, José Moltó, Susana Benet, Lucía Bailón, Jose R Arribas, Alberto M Borobia, Javier Queiruga Parada, Jorge Navarro-Pérez, Maria José Forner Giner, Rafael Ortí Lucas, María del Mar Vázquez Jiménez, Salvador Oña Compán, Melchor Alvarez-Mon, Daniel Troncoso, Eunate Arana-Arri, Susana Meijide, Natale Imaz-Ayo, Patricia Muñoz García, Sofía de la Villa Martínez, Sara Rodríguez Fernández, Teresa Prat, Èlia Torroella, Laura Ferrer
medRxiv 2022.07.05.22277210; doi: https://doi.org/10.1101/2022.07.05.22277210
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
Júlia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Cañete, Antonio Barreiro, Luis González-González, Laia Madrenas, Irina Güell, Bonaventura Clotet, Nuria Izquierdo-Useros, Dàlia Raïch-Regué, Marçal Gallemí, Julià Blanco, Edwards Pradenas, Benjamin Trinité, Julia G Prado, Oscar Blanch-Lombarte, Raúl Pérez-Caballero, Montserrat Plana, Ignasi Esteban, Carmen Pastor-Quiñones, Xavier Núñez-Costa, Rachel Abu Taleb, Paula McSkimming, Alex Soriano, Jocelyn Nava, Jesse Omar Anagua, Rafel Ramos, Ruth Martí Lluch, Aida Corpes Comes, Susana Otero Romero, Xavier Martinez Gomez, Carla Sans-Pola, José Moltó, Susana Benet, Lucía Bailón, Jose R Arribas, Alberto M Borobia, Javier Queiruga Parada, Jorge Navarro-Pérez, Maria José Forner Giner, Rafael Ortí Lucas, María del Mar Vázquez Jiménez, Salvador Oña Compán, Melchor Alvarez-Mon, Daniel Troncoso, Eunate Arana-Arri, Susana Meijide, Natale Imaz-Ayo, Patricia Muñoz García, Sofía de la Villa Martínez, Sara Rodríguez Fernández, Teresa Prat, Èlia Torroella, Laura Ferrer
medRxiv 2022.07.05.22277210; doi: https://doi.org/10.1101/2022.07.05.22277210

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (758)
  • Anesthesia (222)
  • Cardiovascular Medicine (3313)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13397)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5175)
  • Geriatric Medicine (482)
  • Health Economics (785)
  • Health Informatics (3283)
  • Health Policy (1145)
  • Health Systems and Quality Improvement (1198)
  • Hematology (432)
  • HIV/AIDS (1023)
  • Infectious Diseases (except HIV/AIDS) (14651)
  • Intensive Care and Critical Care Medicine (915)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4950)
  • Nursing (262)
  • Nutrition (734)
  • Obstetrics and Gynecology (888)
  • Occupational and Environmental Health (797)
  • Oncology (2530)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1305)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (558)
  • Psychiatry and Clinical Psychology (4223)
  • Public and Global Health (7525)
  • Radiology and Imaging (1713)
  • Rehabilitation Medicine and Physical Therapy (1018)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (72)
  • Transplantation (237)
  • Urology (206)